Rituxan (rituximab)

P3, N=216, Active, not recruiting, Regeneron Pharmaceuticals | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: May 2027 --> May 2028 | Recruiting --> Active, not recruiting

She was treated with prednisone and rituximab and had significant clinical improvement at the time of discharge. This case details an unusual presentation of GPA as a subcarinal mass. It highlights the importance of considering GPA as a possible diagnosis for patients with constitutional symptoms, mediastinal mass, and necrotizing granulomatous inflammation on pathology.

CD79B expression was independently associated with a poor response to R-CHOP therapy in non-GCB DLBCL. The positive association between TERT and LC3 suggests the presence of additional metabolic adaptation mechanisms supporting tumor survival.

R-CHOP immunochemotherapy achieved rapid symptom resolution and complete metabolic response on follow-up PET-CT...When random biopsies fail, multidisciplinary re-evaluation of PET-CT to identify subtle targets for image-guided biopsy is essential for definitive diagnosis. Early recognition of this triad and adoption of a hypothesis-driven biopsy strategy can significantly improve diagnostic outcomes in this elusive lymphoma.

She was treated with rituximab, after which the titer declined to 1:5; however, progressive anemia developed, with hemoglobin falling to 6.5 g/dL, and peripheral blood findings evolved to show left-shifted myeloid maturation with circulating blasts...Published reports of AML presenting with clearly documented cold agglutinin-mediated hemolysis are exceedingly rare. This case underscores that apparent serologic improvement in CAS does not exclude evolving marrow pathology and that worsening cytopenias, persistent macrocytosis, or new peripheral blasts should prompt timely marrow evaluation.

P2, N=32, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting

P1/2, N=58, Not yet recruiting, City of Hope Medical Center

P3, N=640, Recruiting, Ruijin Hospital | Trial completion date: Sep 2025 --> Jun 2028 | Trial primary completion date: Sep 2025 --> Jun 2028

P2, N=10, Not yet recruiting, Mario Negri Institute for Pharmacological Research

Based on these findings, diagnosis was most consistent with FO-LBCL, but distinction from other HHV8-negative effusion-based large B-cell lymphomas remains challenging due to overlapping features. The patient received R-CHOP-based immunochemotherapy and remains clinically stable without systemic progression. This case highlights the critical role of integrated cytologic, immunophenotypic, molecular, and virological analyses in establishing the correct classification of effusion-based large B-cell lymphomas and underscores the diagnostic challenges posed by this emerging entity. Accurate recognition of FO-LBCL is essential, as its clinical behavior and therapeutic implications differ from other effusion-based lymphomas.

P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

Rituximab was discontinued, and the patient was started on azithromycin and airway clearance therapy. Prompt recognition and intervention are crucial for mitigating further lung damage and perhaps full recovery. Pediatricians are encouraged to monitor for rituximab-induced pulmonary complications, particularly in naive lungs.